Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Cash & Equivalents (2016 - 2025)

AtriCure (ATRC) has disclosed Cash & Equivalents for 16 consecutive years, with $167.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 36.43% to $167.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.4 million through Dec 2025, up 36.43% year-over-year, with the annual reading at $167.4 million for FY2025, 36.43% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $167.4 million at AtriCure, up from $147.9 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $167.4 million in Q4 2025, with the low at $28.1 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $84.6 million, with a median of $79.0 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 292.26% in 2021, then crashed 67.04% in 2022.
  • Over 5 years, Cash & Equivalents stood at $43.7 million in 2021, then soared by 33.09% to $58.1 million in 2022, then skyrocketed by 45.11% to $84.3 million in 2023, then skyrocketed by 45.56% to $122.7 million in 2024, then skyrocketed by 36.43% to $167.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $167.4 million, $147.9 million, and $117.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.